Top

Published in:

21-06-2023 | Testosterone | Review

Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

Authors: Rachel Hodan, Linda Rodgers-Fouche, Anu Chittenden, Mev Dominguez-Valentin, James Ferriss, Lauren Gima, Ole-Petter R. Hamnvik, Gregory E. Idos, Kevin Kline, Diane R. Koeller, Jessica M. Long, Danielle McKenna, Charles Muller, Maxton Thoman, Anton Wintner, Bronwyn S. Bedrick, On behalf of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

Published in: Familial Cancer | Issue 4/2023

Abstract

Transgender and gender diverse (TGD) populations with hereditary cancer syndromes face unique obstacles to identifying and obtaining appropriate cancer surveillance and risk-reducing procedures. There is a lack of care provider knowledge about TGD health management. Lynch syndrome (LS) is one of the most common hereditary cancer syndromes, affecting an estimated 1 in 279 individuals. There are no clinical guidelines specific for TGD individuals with LS, highlighting a need to improve the quality of care for this population. There is an urgent need for cancer surveillance recommendations for TGD patients. This commentary provides recommendations for cancer surveillance, risk-reducing strategies, and genetic counseling considerations for TGD patients with LS.

Available only for authorised users

Coleman E, Radix AE, Bouman WP et al (2022) Standards of care for the health of transgender and gender diverse people, version 8. Int J Trans Health 23(Suppl 1):S1–S259. https://doi.org/10.1080/26895269.2022.2100644CrossRef

Herman JL, Flores AR, O’Neill KK (2022) How Many Adults and Youth Identify as Transgender in the United States?

Obedin-Maliver J, Goldsmith ES, Stewart L et al (2011) Lesbian, gay, bisexual, and transgender-related content in undergraduate medical education. JAMA. https://doi.org/10.1001/jama.2011.1255CrossRefPubMed

Dahlhamer JM, Galinsky AM, Joestl SS, Ward BW (2016) Barriers to health care among adults identifying as sexual minorities: a US national study. Am J Public Health 106(6):1116–1122. https://doi.org/10.2105/AJPH.2016.303049CrossRefPubMedPubMedCentral

Lerner JE, Robles G (2017) Perceived barriers and facilitators to health care utilization in the United States for transgender people: a review of recent literature. J Health Care Poor Underserved 28(1):127–152. https://doi.org/10.1353/hpu.2017.0014CrossRefPubMed

Roznovjak D, Petroll AE, Lakatos AEB, Narayan R, Cortina CS (2023) Perceptions of transgender and nonbinary persons toward breast and cervical cancer development, screening, and potential impact on gender-affirming hormone therapy. JCO Oncol Pract 19(5):e794–e800. https://doi.org/10.1200/OP.22.00681CrossRefPubMed

Kiran T, Davie S, Singh D et al (2019) Cancer screening rates among transgender adults: cross-sectional analysis of primary care data. Can Family Phys MEDECIN de famille canadien 65(1):e30–e37

Oladeru OT, Ma SJ, Miccio JA et al (2022) Breast and cervical cancer screening disparities in transgender people. Am J Clin Oncol 45(3):116–121. https://doi.org/10.1097/COC.0000000000000893CrossRefPubMedPubMedCentral

Luehmann N, Ascha M, Chwa E et al (2022) A single-center study of adherence to breast cancer screening mammography guidelines by transgender and non-binary patients. Ann Surg Oncol 29(3):1707–1717. https://doi.org/10.1245/s10434-021-10932-zCrossRefPubMed

10.

National Academies of Sciences Engineering and Medicine (2020). In: White J, Sepulveda MJ, Patterson CJ (eds) Understanding the well-being of lgbtqi populations the national academies collection: reports funded by national institutes of health. The National Academies Press, Washington

11.

Jackson SS, Han X, Mao Z et al (2021) Cancer stage, treatment, and survival among transgender patients in the United States. J Natl Cancer Inst 113(9):1221–1227. https://doi.org/10.1093/jnci/djab028CrossRefPubMedPubMedCentral

12.

Griggs J, Maingi S, Blinder V et al (2017) American society of clinical oncology position statement: strategies for reducing cancer health disparities among sexual and gender minority populations. J Clin Oncol 35(19):2203–2208. https://doi.org/10.1200/JCO.2016.72.0441CrossRefPubMed

13.

Sakradse M, Zhu S, Ritterman Weintraub M, Jung J, Zaritsky E (2022) Hereditary breast and ovarian cancer genetic risk: screening and treatment among transgender and gender diverse patients. Perm J 26(3):30–38. https://doi.org/10.7812/TPP/21.133CrossRefPubMedPubMedCentral

14.

Bedrick BS, Fruhauf TF, Martin SJ, Ferriss JS (2021) Creating breast and gynecologic cancer guidelines for transgender patients with BRCA mutations. Obstet Gynecol 138(6):911–917. https://doi.org/10.1097/AOG.0000000000004597CrossRefPubMed

15.

Pearlman R, Frankel WL, Swanson BJ et al (2021) Prospective statewide study of universal screening for hereditary colorectal cancer: the ohio colorectal cancer prevention initiative. JCO Precision Oncol. https://doi.org/10.1200/PO.20.00525CrossRef

16.

Ryan NAJ, Glaire MA, Blake D, Cabrera-Dandy M, Evans DG, Crosbie EJ (2019) The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med 21(10):2167–2180. https://doi.org/10.1038/s41436-019-0536-8CrossRefPubMedPubMedCentral

17.

Ligtenberg MJL, Kuiper RP, Geurts van Kessel A, Hoogerbrugge N (2013) EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer 12(2):169–174. https://doi.org/10.1007/s10689-012-9591-xCrossRefPubMed

18.

Win AK, Jenkins MA, Dowty JG et al (2017) Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomark Prev 26(3):404–412. https://doi.org/10.1158/1055-9965.EPI-16-0693CrossRef

19.

Møller P, Seppälä TT, Bernstein I et al (2018) Cancer risk and survival in <i>path_MMR</i> carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database. Gut 67(7):1306–1316. https://doi.org/10.1136/gutjnl-2017-314057CrossRefPubMed

20.

Dominguez-Valentin M, Haupt S, Seppala TT et al (2023) Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database. EClinicalMedicine 58:101909. https://doi.org/10.1016/j.eclinm.2023.101909CrossRefPubMedPubMedCentral

21.

Gupta S, Weiss JM, Burke CA, et al. (2022) NCCN Guidelines Version 2.2022 Genetic/Familial High-Risk Assessment: Colorectal. https://www.nccn.org/home/

22.

Safer JD, Tangpricha V (2019) Care of the transgender patient. Annals Internal Med. https://doi.org/10.7326/AITC201907020CrossRef

23.

Hembree WC, Cohen-Kettenis PT, Gooren L et al (2017) Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 102(11):3869–3903. https://doi.org/10.1210/jc.2017-01658CrossRefPubMed

24.

Baker KE, Wilson LM, Sharma R, Dukhanin V, McArthur K, Robinson KA (2021) Hormone therapy, mental health, and quality of life among transgender people: a systematic review. J Endocr Soc. https://doi.org/10.1210/jendso/bvab011CrossRefPubMedPubMedCentral

25.

Masumori N, Baba T, Abe T, Niwa K (2021) What is the most anticipated change induced by treatment using gender-affirming hormones in individuals with gender incongruence? Int J Urol 28(5):526–529. https://doi.org/10.1111/iju.14499CrossRefPubMed

26.

Irwig MS (2017) Testosterone therapy for transgender men. Lancet Diabetes Endocrinol 5(4):301–311. https://doi.org/10.1016/S2213-8587(16)00036-XCrossRefPubMed

27.

Schechter LS, Safa B (2018) Gender surgery: a truly multidisciplinary field. Clin Plastic Surg. https://doi.org/10.1016/j.cps.2018.05.001CrossRef

28.

de Blok CJM, Klaver M, Wiepjes CM et al (2018) breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. J Clin Endocrinol Metab 103(2):532–538. https://doi.org/10.1210/jc.2017-01927CrossRefPubMed

29.

Cocchetti C, Ristori J, Romani A, Maggi M, Fisher AD (2020) Hormonal Treatment strategies tailored to non-binary transgender individuals. J Clin Med. https://doi.org/10.3390/jcm9061609CrossRefPubMedPubMedCentral

30.

Fernandez E, La Vecchia C, Braga C et al (1998) Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 7(4):329–333PubMed

31.

Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB (2009) Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol 27(27):4542–4547. https://doi.org/10.1200/JCO.2009.22.0764CrossRefPubMedPubMedCentral

32.

Johnson JR, Lacey JV Jr, Lazovich D et al (2009) Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 18(1):196–203. https://doi.org/10.1158/1055-9965.EPI-08-0596CrossRefPubMedPubMedCentral

33.

Jang YC, Huang HL, Leung CY (2019) Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis. BMC Cancer 19(1):1199. https://doi.org/10.1186/s12885-019-6428-0CrossRefPubMedPubMedCentral

34.

Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg LJ, Nilbert M (2017) Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br J Cancer 117(11):1702–1710. https://doi.org/10.1038/bjc.2017.348CrossRefPubMedPubMedCentral

35.

Kim J, Braun D, Ukaegbu C et al (2020) Clinical factors associated with gastric cancer in individuals with lynch syndrome. Clin Gastroenterol Hepatol 18(4):830–7.e1. https://doi.org/10.1016/j.cgh.2019.07.012CrossRefPubMed

36.

Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262. https://doi.org/10.1038/ajg.2014.435CrossRefPubMedPubMedCentral

37.

Lopez DS, Malagaris I, Polychronopoulou E et al (2022) Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men. Clin Endocrinol 97(6):792–803. https://doi.org/10.1111/cen.14803CrossRef

38.

Liu Q, Simin J, Debelius J et al (2021) Menopausal hormone therapies and risk of colorectal cancer: a Swedish matched-cohort study. Aliment Pharmacol Ther 53(11):1216–1225. https://doi.org/10.1111/apt.16362CrossRefPubMed

39.

Bosetti C, Bravi F, Negri E, La Vecchia C (2009) Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 15(5):489–498. https://doi.org/10.1093/humupd/dmp017CrossRefPubMed

40.

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004. https://doi.org/10.1056/NEJMoa032071CrossRefPubMed

41.

Lin KJ, Cheung WY, Lai JY-C, Giovannucci EL (2012) The effect of estrogen vs. Combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 130(2):419–430. https://doi.org/10.1002/ijc.26026CrossRefPubMed

42.

Kita Y, Mori S, Baba K et al (2015) Mucinous adenocarcinoma emerging in sigmoid colon neovagina 40 years after its creation: a case report. World J Surg Oncol 13:213. https://doi.org/10.1186/s12957-015-0636-0CrossRefPubMedPubMedCentral

43.

Yamada K, Shida D, Kato T, Yoshida H, Yoshinaga S, Kanemitsu Y (2018) Adenocarcinoma arising in sigmoid colon neovagina 53 years after construction. World J Surg Oncol 16(1):88. https://doi.org/10.1186/s12957-018-1372-zCrossRefPubMedPubMedCentral

44.

Sun XF, Miao XX, Li BX, Wang Y (2022) Cervical and endometrial cancers of intestinal origin diagnosed 18 years after vaginal replacement with a sigmoid colon segment: a case report and review of the literature. Front Oncol. https://doi.org/10.3389/fonc.2022.912236CrossRefPubMedPubMedCentral

45.

Lu KH, Broaddus RR (2005) Gynecologic cancers in Lynch Syndrome/HNPCC. Fam Cancer 4(3):249–254. https://doi.org/10.1007/s10689-005-1838-3CrossRefPubMed

46.

Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT (1994) The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 96(6):516–520. https://doi.org/10.1016/0002-9343(94)90091-4CrossRefPubMed

47.

Watson P, Lynch HT (2001) Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 1(1):57–60. https://doi.org/10.1023/a:1011590617833CrossRefPubMed

48.

Futterweit W, Deligdisch L (1986) Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 62(1):16–21. https://doi.org/10.1210/jcem-62-1-16CrossRefPubMed

49.

Stenzel AE, Moysich KB, Ferrando CA, Starbuck KD (2020) Clinical needs for transgender men in the gynecologic oncology setting. Gynecol Oncol 159(3):899–905. https://doi.org/10.1016/j.ygyno.2020.09.038CrossRefPubMedPubMedCentral

50.

Asseler JD, Caanen MR, Verhoeven MO et al (2022) Endometrial thickness assessed by transvaginal ultrasound in transmasculine people taking testosterone compared with cisgender women. Reprod Biomed Online 45(5):1033–1038. https://doi.org/10.1016/j.rbmo.2022.06.012CrossRefPubMed

51.

Grimstad FW, Fowler KG, New EP et al (2019) Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2018.12.021CrossRefPubMed

52.

Hawkins M, Deutsch MB, Obedin-Maliver J et al (2021) Endometrial findings among transgender and gender nonbinary people using testosterone at the time of gender-affirming hysterectomy. Fertil Steril 115(5):1312–1317. https://doi.org/10.1016/j.fertnstert.2020.11.008CrossRefPubMed

53.

Rachlin K, Green J, Lombardi E (2008) Utilization of health care among female-to-male transgender individuals in the United States. J Homosex 54(3):243–258. https://doi.org/10.1080/00918360801982124CrossRefPubMed

54.

Pelusi C, Costantino A, Martelli V et al (2014) Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med 11(12):3002–3011. https://doi.org/10.1111/jsm.12698CrossRefPubMed

55.

Grimstad F, Kremen J, Shim J, Charlton BM, Boskey ER (2021) Breakthrough bleeding in transgender and gender diverse adolescents and young adults on long-term testosterone. J Pediatr Adolesc Gynecol 34(5):706–716. https://doi.org/10.1016/j.jpag.2021.04.004CrossRefPubMed

56.

Bobola A, Gorzelak-Magiera A, Steinhof-Radwańska K, Lorek A, Kliber M, Gisterek I (2021) Genetically burdened transgender man during gender reassignment process with two primary neoplasms: a case report. Oncology in Clinical Practice 17(4):183–186. https://doi.org/10.5603/OCP.2021.0009CrossRef

57.

Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S (2012) Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer 19(6):R255–R279. https://doi.org/10.1530/ERC-12-0175CrossRefPubMedPubMedCentral

58.

Aubrey C, Saad N, Kobel M, Mattatall F, Nelson G, Glaze S (2021) Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status. Gynecol Oncol 161(2):342–346. https://doi.org/10.1016/j.ygyno.2021.02.019CrossRefPubMed

59.

Ness RB (2003) Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189(1):280–294. https://doi.org/10.1067/mob.2003.408CrossRefPubMed

60.

Grimstad FW, Fowler KG, New EP et al (2020) Ovarian histopathology in transmasculine persons on testosterone: a multicenter case series. J Sex Med 17(9):1807–1818. https://doi.org/10.1016/j.jsxm.2020.05.029CrossRefPubMedPubMedCentral

61.

Taylor ET, Bryson MK (2016) Cancer’s margins: trans* and gender nonconforming people’s access to knowledge, experiences of cancer health, and decision-making. LGBT Health 3(1):79–89. https://doi.org/10.1089/lgbt.2015.0096CrossRefPubMedPubMedCentral

62.

Hage JJ, Dekker JJ, Karim RB, Verheijen RH, Bloemena E (2000) Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol 76(3):413–415. https://doi.org/10.1006/gyno.1999.5720CrossRefPubMed

63.

Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO (2006) Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest 62(4):226–228. https://doi.org/10.1159/000094097CrossRefPubMed

64.

Ferreira C, Fraga J, Antunes C, Goncalo M, Donato P (2021) Serous borderline tumor in transgender female-to-male individuals: a case report of androgen receptor-positive ovarian cancer. Case Rep Radiol 2021:8861692. https://doi.org/10.1155/2021/8861692CrossRefPubMedPubMedCentral

65.

Millington K, Hayes K, Pilcher S et al (2021) A serous borderline ovarian tumour in a transgender male adolescent. Br J Cancer 124(3):567–569. https://doi.org/10.1038/s41416-020-01129-4CrossRefPubMed

66.

Chene G, Rahimi K, Mes-Masson AM, Provencher D (2013) Surgical implications of the potential new tubal pathway for ovarian carcinogenesis. J Minim Invasive Gynecol 20(2):153–159. https://doi.org/10.1016/j.jmig.2012.11.010CrossRefPubMed

67.

Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA (2013) Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer 23(3):417–421. https://doi.org/10.1097/IGC.0b013e3182849dbaCrossRefPubMed

68.

Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116(6):1453–1456. https://doi.org/10.1016/s0016-5085(99)70510-xCrossRefPubMed

69.

Skeldon SC, Semotiuk K, Aronson M et al (2013) Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 63(2):379–385. https://doi.org/10.1016/j.eururo.2012.07.047CrossRefPubMed

70.

van der Post RS, Kiemeney LA, Ligtenberg MJ et al (2010) Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 47(7):464–470. https://doi.org/10.1136/jmg.2010.076992CrossRefPubMed

71.

Joost P, Therkildsen C, Dominguez-Valentin M, Jonsson M, Nilbert M (2015) Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 86(6):1212–1217. https://doi.org/10.1016/j.urology.2015.08.018CrossRefPubMed

72.

Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M (2017) Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev 39(1):93–107. https://doi.org/10.1093/epirev/mxw003CrossRefPubMedPubMedCentral

73.

Siegel R, Naishadham D (2012) Jemal A (2012) cancer statistics. CA Cancer J Clin 62(1):10–29. https://doi.org/10.3322/caac.20138CrossRefPubMed

74.

Shariat SF, Favaretto RL, Gupta A et al (2011) Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 29(4):481–486. https://doi.org/10.1007/s00345-010-0594-7CrossRefPubMed

75.

Buchting FO, Emory KT, Scout, et al (2017) Transgender use of cigarettes, cigars, and e-cigarettes in a national study. Am J Prev Med 53(1):e1–e7. https://doi.org/10.1016/j.amepre.2016.11.022CrossRefPubMedPubMedCentral

76.

D’Avanzo B, La Vecchia C, Negri E, Decarli A, Benichou J (1995) Attributable risks for bladder cancer in northern Italy. Ann Epidemiol 5(6):427–431. https://doi.org/10.1016/1047-2797(95)00057-7CrossRefPubMed

77.

Hartge P, Silverman D, Hoover R et al (1987) Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst 78(6):1119–1125PubMed

78.

Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306(7):737–745. https://doi.org/10.1001/jama.2011.1142CrossRefPubMedPubMedCentral

79.

Hartge P, Harvey EB, Linehan WM et al (1990) Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 82(20):1636–1640. https://doi.org/10.1093/jnci/82.20.1636CrossRefPubMed

80.

Dobruch J, Daneshmand S, Fisch M et al (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69(2):300–310. https://doi.org/10.1016/j.eururo.2015.08.037CrossRefPubMed

81.

Kwon H, Schafer JM, Song NJ et al (2022) Androgen conspires with the CD8(+) T cell exhaustion program and contributes to sex bias in cancer. Sci Immunol. https://doi.org/10.1126/sciimmunol.abq2630CrossRefPubMedPubMedCentral

82.

Lutz CT, Livas L, Presnell SR, Sexton M, Wang P (2021) Gender differences in urothelial bladder cancer: effects of natural killer lymphocyte immunity. J Clin Med: https://doi.org/10.3390/jcm10215163CrossRefPubMedPubMedCentral

83.

Kaneko S, Li X (2018) X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. Sci Adv. https://doi.org/10.1126/sciadv.aar5598CrossRefPubMedPubMedCentral

84.

Grindedal EM, Moller P, Eeles R et al (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18(9):2460–2467. https://doi.org/10.1158/1055-9965.EPI-09-0058CrossRefPubMed

85.

Dominguez-Valentin M, Sampson JR, Seppala TT et al (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective lynch syndrome database. Genet Med 22(1):15–25. https://doi.org/10.1038/s41436-019-0596-9CrossRefPubMed

86.

Rosty C, Walsh MD, Lindor NM et al (2014) High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry. Fam Cancer 13(4):573–582. https://doi.org/10.1007/s10689-014-9744-1CrossRefPubMedPubMedCentral

87.

Dominguez-Valentin M, Joost P, Therkildsen C, Jonsson M, Rambech E, Nilbert M (2016) Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol 16:15. https://doi.org/10.1186/s12894-016-0130-1CrossRefPubMedPubMedCentral

88.

Ingham MD, Lee RJ, MacDermed D, Olumi AF (2018) Prostate cancer in transgender women. Urol Oncol 36(12):518–525. https://doi.org/10.1016/j.urolonc.2018.09.011CrossRefPubMed

89.

Deebel NA, Morin JP, Autorino R, Vince R, Grob B, Hampton LJ (2017) Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges. Urology 110:166–171. https://doi.org/10.1016/j.urology.2017.08.032CrossRefPubMed

90.

Gooren L, Morgentaler A (2014) Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia 46(10):1156–1160. https://doi.org/10.1111/and.12208CrossRefPubMed

91.

Joint R, Chen ZE, Cameron S (2018) Breast and reproductive cancers in the transgender population: a systematic review. BJOG 125(12):1505–1512. https://doi.org/10.1111/1471-0528.15258CrossRefPubMed

92.

Weyers S, De Sutter P, Hoebeke S et al (2010) Gynaecological aspects of the treatment and follow-up of transsexual men and women. Facts Views Vis Obgyn 2(1):35–54PubMedPubMedCentral

93.

Crowley F, Mihalopoulos M, Gaglani S et al (2023) Prostate cancer in transgender women: considerations for screening, diagnosis and management. Br J Cancer 128(2):177–189. https://doi.org/10.1038/s41416-022-01989-yCrossRefPubMed

94.

Buerki N, Gautier L, Kovac M et al (2012) Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer 51(1):83–91. https://doi.org/10.1002/gcc.20935CrossRefPubMed

95.

Harkness EF, Barrow E, Newton K et al (2015) Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. J Med Genet 52(8):553–556. https://doi.org/10.1136/jmedgenet-2015-103216CrossRefPubMed

96.

Roberts ME, Jackson SA, Susswein LR et al (2018) MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. Genet Med 20(10):1167–1174. https://doi.org/10.1038/gim.2017.254CrossRefPubMedPubMedCentral

97.

Stoll J, Rosenthal E, Cummings S, Willmott J, Bernhisel R, Kupfer SS (2020) No evidence of increased risk of breast cancer in women with lynch syndrome identified by multigene panel testing. JCO Precis Oncol 4:51–60. https://doi.org/10.1200/PO.19.00271CrossRefPubMed

98.

Hu C, Hart SN, Gnanaolivu R et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384(5):440–451. https://doi.org/10.1056/NEJMoa2005936CrossRefPubMedPubMedCentral

99.

Slavin TP, Maxwell KN, Lilyquist J et al (2017) The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 3:22. https://doi.org/10.1038/s41523-017-0024-8CrossRefPubMedPubMedCentral

100.

Brown GR, Jones KT (2015) Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 149(1):191–198. https://doi.org/10.1007/s10549-014-3213-2CrossRefPubMed

101.

Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ (2013) Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 10(12):3129–3134. https://doi.org/10.1111/jsm.12319CrossRefPubMed

102.

de Blok CJM, Wiepjes CM, Nota NM et al (2019) Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. https://doi.org/10.1136/bmj.l1652CrossRefPubMedPubMedCentral

103.

Deutsch MB, (Ed.) (2016) Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. https://transcare.ucsf.edu/guidelines

104.

Makadon H, Potter J, Mayer K, Goldhammer H (eds) (2015) The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health, 2nd edn. American College of Physicians, Philadelphia

105.

Parikh U, Mausner E, Chhor CM, Gao Y, Karrington I, Heller SL (2020) Breast imaging in transgender patients: what the radiologist should know. Radiographics 40(1):13–27. https://doi.org/10.1148/rg.2020190044CrossRefPubMed

106.

University Hospitals (2018) Transgender Breast Cancer Screenings. https://www.uhhospitals.org/services/cancer-services/breast-cancer/transgender-breast-screenings

107.

Expert Panel on Breast Imaging, Brown A, Lourenco AP et al (2021) ACR Appropriateness criteria(R) transgender breast cancer screening. J Am Coll Radiol 18(11S):S502–S515. https://doi.org/10.1016/j.jacr.2021.09.005CrossRef

108.

Ren W, Chen M, Qiao Y, Zhao F (2022) Global guidelines for breast cancer screening: a systematic review. Breast 64:85–99. https://doi.org/10.1016/j.breast.2022.04.003CrossRefPubMedPubMedCentral

109.

Rolle L, Zayhowski K, Koeller D, Chiluiza D, Carmichael N (2022) Transgender patients’ perspectives on their cancer genetic counseling experiences. J Genet Couns 31(3):781–791. https://doi.org/10.1002/jgc4.1544CrossRefPubMed

110.

Zayhowski K, Park J, Boehmer U, Gabriel C, Berro T, Campion M (2019) Cancer genetic counselors’ experiences with transgender patients: a qualitative study. J Genet Couns. https://doi.org/10.1002/jgc4.1092CrossRefPubMed

111.

Kano M, Jaffe SA, Rieder S et al (2022) Improving sexual and gender minority cancer care: patient and caregiver perspectives from a multi-methods pilot study. Front Oncol. https://doi.org/10.3389/fonc.2022.833195CrossRefPubMedPubMedCentral

112.

Obedin-Maliver J, de Haan G (2017) Gynecologic care for transgender adults. Curre Obstet Gynecol Rep 6(2):140–148. https://doi.org/10.1007/s13669-017-0204-4CrossRef

113.

The GLBT Health Access Project (1997) Community Standards of Practice for the Provision of Quality Health Care Services for Gay, Lesbian, Bisexual and Transgendered Clients. http://www.glbthealth.org/CommunityStandardsofPractice.htm

114.

Grasso C, Goldhammer H, Funk D et al (2019) Required sexual orientation and gender identity reporting by us health centers: first-year data. Am J Public Health 109(8):1111–1118. https://doi.org/10.2105/AJPH.2019.305130CrossRefPubMedPubMedCentral

115.

Streed CG Jr, Grasso C, Reisner SL, Mayer KH (2020) Sexual orientation and gender identity data collection: clinical and public health importance. Am J Public Health 110(7):991–993. https://doi.org/10.2105/ajph.2020.305722CrossRefPubMedCentral

116.

Alpert AB, Mehringer JE, Orta SJ et al (2022) Experiences of transgender people reviewing their electronic health records, a qualitative study. J Gen Intern Med. https://doi.org/10.1007/s11606-022-07671-6CrossRefPubMedPubMedCentral

117.

Bennett RL, French KS, Resta RG, Austin J (2022) Practice resource-focused revision: Standardized pedigree nomenclature update centered on sex and gender inclusivity: a practice resource of the national society of genetic counselors. J Genet Couns 31(6):1238–1248. https://doi.org/10.1002/jgc4.1621CrossRefPubMed

118.

Pritchard D, Goodman C, Nadauld LD (2022) Clinical utility of genomic testing in cancer care. JCO Precis Oncol. https://doi.org/10.1200/PO.21.00349CrossRefPubMedPubMedCentral

119.

National Society of Genetic Counselors (2018) Genetic Testing of Minors for Adult-Onset Conditions. https://www.nsgc.org/Policy-Research-and-Publications/Position-Statements/Position-Statements/Post/genetic-testing-of-minors-for-adult-onset-conditions

120.

Holter S, Hall MJ, Hampel H et al (2022) Risk assessment and genetic counseling for Lynch syndrome–practice resource of the national society of genetic counselors and the collaborative group of the americas on inherited gastrointestinal cancer. J Genet Couns 31(3):568–583. https://doi.org/10.1002/jgc4.1546CrossRefPubMed

121.

Baram S, Myers SA, Yee S, Librach CL (2019) Fertility preservation for transgender adolescents and young adults: a systematic review. Hum Reprod Update 25(6):694–716. https://doi.org/10.1093/humupd/dmz026CrossRefPubMed

122.

Mayhew AC, Gomez-Lobo V (2020) Fertility options for the transgender and gender nonbinary patient. J Clin Endocrinol Metab 105(10):3335–3345. https://doi.org/10.1210/clinem/dgaa529CrossRefPubMedPubMedCentral

123.

The American College of Obstetricians and Gynecologists (2018) ACOG Committee opinion No. 749: marriage and family building equality for lesbian, gay, bisexual, transgender, queer, intersex, asexual, and gender nonconforming individuals. Obstet Gynecol. https://doi.org/10.1097/AOG.0000000000002765CrossRef

124.

Rich TA, Liu M, Etzel CJ et al (2014) Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13(2):291–299. https://doi.org/10.1007/s10689-013-9685-0CrossRefPubMedPubMedCentral

125.

Fesahat F, Montazeri F, Hoseini SM (2020) Preimplantation genetic testing in assisted reproduction technology. J Gynecol Obstet Hum Reprod 49(5):101723. https://doi.org/10.1016/j.jogoh.2020.101723CrossRefPubMed

126.

Grimstad F, Boskey ER, Taghinia A, Ganor O (2021) Gender-affirming surgeries in transgender and gender diverse adolescent and young adults: a pediatric and adolescent gynecology primer. J Pediatr Adolesc Gynecol 34(4):442–448. https://doi.org/10.1016/j.jpag.2021.03.014CrossRefPubMed

127.

Center for Substance Abuse Treatment (US) (2014) Trauma-Informed Care in Behavioral Health Services. Rockville (MD). Treatment Improvement Protocol (TIP) Series, No. 57. Substance Abuse and Mental Health Services Administration (US);. https://www.ncbi.nlm.nih.gov/books/NBK207201/

128.

Iwamoto SJ, Defreyne J, Rothman MS et al (2019) Health considerations for transgender women and remaining unknowns: a narrative review. Ther Adv Endocrinol Metab 10:2042018819871166. https://doi.org/10.1177/2042018819871166CrossRefPubMedPubMedCentral

Title: Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer
Authors: Rachel Hodan
Linda Rodgers-Fouche
Anu Chittenden
Mev Dominguez-Valentin
James Ferriss
Lauren Gima
Ole-Petter R. Hamnvik
Gregory E. Idos
Kevin Kline
Diane R. Koeller
Jessica M. Long
Danielle McKenna
Charles Muller
Maxton Thoman
Anton Wintner
Bronwyn S. Bedrick
On behalf of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer
Publication date: 21-06-2023
Publisher: Springer Netherlands
Keyword: Testosterone
Published in: Familial Cancer / Issue 4/2023
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-023-00341-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer

Mainstreamed genetic testing of breast cancer patients: experience from a single surgeon’s practice in a large US Academic Center

In deep bioinformatic characterization of a novel fumarate hydratase variant FH c.199T > G; (p.Tyr67Asp) in hereditary leiomyomatosis and renal cell carcinoma

Willingness of individuals with Li-Fraumeni syndrome to participate in a cancer prevention trial: a survey study

Unusual phenotypes in patients with a pathogenic germline variant in DICER1

A mosaic pathogenic variant in MSH6 causes MSH6-deficient colorectal and endometrial cancer in a patient classified as suspected Lynch syndrome: a case report

Keynote webinar | Spotlight on antibody–drug conjugates in cancer